160 related articles for article (PubMed ID: 30957954)
41. Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.
Ishikawa M; Furuuchi T; Yamauchi M; Yokoyama F; Kakui N; Sato Y
Bioorg Med Chem; 2010 Jul; 18(14):5441-8. PubMed ID: 20541426
[TBL] [Abstract][Full Text] [Related]
42. Histamine H
Ghamari N; Zarei O; Arias-Montaño JA; Reiner D; Dastmalchi S; Stark H; Hamzeh-Mivehroud M
Pharmacol Ther; 2019 Aug; 200():69-84. PubMed ID: 31028835
[TBL] [Abstract][Full Text] [Related]
43. Metabolic benefits of novel histamine H
Mika K; Szafarz M; Bednarski M; Kuder K; Szczepańska K; Pociecha K; Pomierny B; Kieć-Kononowicz K; Sapa J; Kotańska M
Biomed Pharmacother; 2021 Oct; 142():111952. PubMed ID: 34325303
[TBL] [Abstract][Full Text] [Related]
44. Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.
Tao M; Aimone LD; Huang Z; Mathiasen J; Raddatz R; Lyons J; Hudkins RL
J Med Chem; 2012 Jan; 55(1):414-23. PubMed ID: 22107017
[TBL] [Abstract][Full Text] [Related]
45. From an atypical wake-promoting agent to potent histamine-3 receptor inverse agonists.
Dunn D; Raddatz R; Ator MA; Bacon ER; Chatterjee S
Chem Biol Drug Des; 2013 Mar; 81(3):433-5. PubMed ID: 23205610
[TBL] [Abstract][Full Text] [Related]
46. Lead optimization of thiazolo[5,4-c]piperidines: 3-cyclobutoxy linker as a key spacer for H(3)R inverse agonists.
Provins L; Denonne F; Célanire S; Christophe B; Defays S; Delaunoy C; Delporte ML; Demaude T; Durieu V; Gillard M; Hubert D; Lamberty Y; Lorent G; Valade A; Vanbellinghen A; Van Houtvin N
ChemMedChem; 2012 Dec; 7(12):2087-92. PubMed ID: 23042668
[TBL] [Abstract][Full Text] [Related]
47. Role of the Histamine H
Schlicker E; Kathmann M
Handb Exp Pharmacol; 2017; 241():277-299. PubMed ID: 27787717
[TBL] [Abstract][Full Text] [Related]
48. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
[TBL] [Abstract][Full Text] [Related]
49. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
50. Discovery of spirofused piperazine and diazepane amides as selective histamine-3 antagonists with in vivo efficacy in a mouse model of cognition.
Brown DG; Bernstein PR; Griffin A; Wesolowski S; Labrecque D; Tremblay MC; Sylvester M; Mauger R; Edwards PD; Throner SR; Folmer JJ; Cacciola J; Scott C; Lazor LA; Pourashraf M; Santhakumar V; Potts WM; Sydserff S; Giguère P; Lévesque C; Dasser M; Groblewski T
J Med Chem; 2014 Feb; 57(3):733-58. PubMed ID: 24410637
[TBL] [Abstract][Full Text] [Related]
51. 4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.
Hudkins RL; Aimone LD; Dandu RR; Dunn D; Gruner JA; Huang Z; Josef KA; Lyons JA; Mathiasen JR; Tao M; Zulli AL; Raddatz R
Bioorg Med Chem Lett; 2012 Jan; 22(1):194-8. PubMed ID: 22142542
[TBL] [Abstract][Full Text] [Related]
52. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.
Ishikawa M; Watanabe T; Kudo T; Yokoyama F; Yamauchi M; Kato K; Kakui N; Sato Y
J Med Chem; 2010 Sep; 53(17):6445-56. PubMed ID: 20690643
[TBL] [Abstract][Full Text] [Related]
53. 4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists.
Wijtmans M; Celanire S; Snip E; Gillard MR; Gelens E; Collart PP; Venhuis BJ; Christophe B; Hulscher S; van der Goot H; Lebon F; Timmerman H; Bakker RA; Lallemand BI; Leurs R; Talaga PE; de Esch IJ
J Med Chem; 2008 May; 51(10):2944-53. PubMed ID: 18433114
[TBL] [Abstract][Full Text] [Related]
54. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
[TBL] [Abstract][Full Text] [Related]
55. Discovery of a new class of non-imidazole oxazoline-based histamine H(3) receptor (H(3)R) inverse agonists.
Célanire S; Wijtmans M; Christophe B; Collart P; de Esch I; Dassesse D; Delaunoy C; Denonne F; Durieu V; Gelens E; Gillard M; Lallemand B; Lamberty Y; Lebon F; Nicolas JM; Quéré L; Snip E; Vanbellinghen A; Van Houtvin N; Verbois V; Timmerman H; Talaga P; Leurs R; Provins L
ChemMedChem; 2009 Jul; 4(7):1063-8. PubMed ID: 19405064
[TBL] [Abstract][Full Text] [Related]
56. Pitolisant for treating patients with narcolepsy.
Li S; Yang J
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):79-84. PubMed ID: 31937172
[No Abstract] [Full Text] [Related]
57. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
Le S; Gruner JA; Mathiasen JR; Marino MJ; Schaffhauser H
J Pharmacol Exp Ther; 2008 Jun; 325(3):902-9. PubMed ID: 18305012
[TBL] [Abstract][Full Text] [Related]
58. Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.
Witte DG; Yao BB; Miller TR; Carr TL; Cassar S; Sharma R; Faghih R; Surber BW; Esbenshade TA; Hancock AA; Krueger KM
Br J Pharmacol; 2006 Jul; 148(5):657-70. PubMed ID: 16715122
[TBL] [Abstract][Full Text] [Related]
59. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.
Covel JA; Santora VJ; Smith JM; Hayashi R; Gallardo C; Weinhouse MI; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Pulley MD; Smith BM; Ren A; Suarez M; Frazer J; Edwards J; Hauser EK; Lorea J; Semple G; Grottick AJ
J Med Chem; 2009 Sep; 52(18):5603-11. PubMed ID: 19722526
[TBL] [Abstract][Full Text] [Related]
60. 5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity.
Pierson PD; Fettes A; Freichel C; Gatti-McArthur S; Hertel C; Huwyler J; Mohr P; Nakagawa T; Nettekoven M; Plancher JM; Raab S; Richter H; Roche O; Rodríguez Sarmiento RM; Schmitt M; Schuler F; Takahashi T; Taylor S; Ullmer C; Wiegand R
J Med Chem; 2009 Jul; 52(13):3855-68. PubMed ID: 19456097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
